What is the optimal intraoperative management of group III pulmonary hypertension during anesthesia?

Intraoperative Management of Group 3 Pulmonary Hypertension

Continue all chronic pulmonary vasodilator therapies (phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclins) throughout the perioperative period without interruption, and focus on preventing right ventricular failure through meticulous hemodynamic management rather than initiating new PH-specific therapies intraoperatively 1, 2, 3.

Critical Context: Group 3 PH is Different

Group 3 pulmonary hypertension (PH due to lung disease/hypoxia) presents unique challenges compared to Group 1 PAH. The evidence base is weaker for Group 3, and PAH-targeted therapies are not approved in Europe for Group 3 PH 4. However, the fundamental principles of preventing right ventricular (RV) decompensation remain paramount.

Preoperative Optimization

Ensure patients are managed at centers with PH expertise 1. Key preoperative assessments include:

• Recent right heart catheterization data (mean PA pressure, pulmonary vascular resistance)
• Echocardiographic evaluation of RV function and severity of dysfunction
• WHO functional class (Class III-IV indicates higher risk)
• Optimization of underlying lung disease and hypoxemia 1

Do not withhold chronic PH medications for fasting - convert to IV or nebulized formulations if enteral absorption is unreliable 1.

Intraoperative Hemodynamic Goals

The cornerstone of management is preventing RV failure by avoiding factors that increase pulmonary vascular resistance (PVR) 5, 6:

Absolute Priorities to Prevent PVR Increase:

• Maintain normoxia (avoid hypoxemia at all costs)
• Prevent hypercarbia (maintain PaCO₂ 35-40 mmHg)
• Avoid acidosis (metabolic or respiratory)
• Maintain normothermia
• Avoid hypervolemia (RV is preload-sensitive but volume-intolerant)
• Minimize intrathoracic pressure (avoid high PEEP, aggressive ventilation)

Hemodynamic Targets:

• Maintain systemic blood pressure to preserve RV coronary perfusion
• Avoid excessive RV preload (judicious fluid management)
• Support RV contractility when needed with dobutamine as first-line inotrope 7, 1

Monitoring Strategy

Invasive arterial monitoring is essential 8. For intermediate-to-high risk cases:

• Central venous catheter for CVP monitoring and vasoactive drug administration 3
• Consider pulmonary artery catheter in high-risk cases, though placement requires expertise and carries risks 3
• Transesophageal echocardiography provides superior real-time assessment of RV function and volume status 9

Anesthetic Technique

Avoid deep anesthesia and excessive sympathetic blockade which exacerbate hypotension 8. Consider:

• Balanced anesthesia with careful titration
• Neuraxial techniques (spinal/epidural) can be considered as alternatives to general anesthesia in select cases, though require meticulous vasopressor management 10
• Co-induction techniques to minimize hemodynamic swings 8

Vasopressor/Inotrope Management

When hypotension occurs (common with anesthetic induction):

• Vasopressors with alpha-agonist activity (phenylephrine, norepinephrine) to maintain systemic pressure and RV perfusion
• Avoid pure beta-agonists that may worsen RV-PA coupling
• Dobutamine for RV inotropic support if RV dysfunction develops 7, 1

Pulmonary Vasodilator Therapy

Inhaled pulmonary vasodilators may be reasonable for elevated-risk cases to reduce RV afterload 3:

• Inhaled nitric oxide (iNO)
• Aerosolized prostacyclins (epoprostenol, iloprost)
• These provide selective pulmonary vasodilation without systemic hypotension 11

However, starting new systemic PH-specific therapies intraoperatively has not been established and is not recommended 1.

Common Pitfalls

1. Fluid overload: The failing RV cannot accommodate excessive preload - use goal-directed fluid therapy
2. Hypoxemia/hypercarbia: Even brief episodes dramatically increase PVR
3. Discontinuing chronic PH medications: This precipitates acute decompensation
4. Inadequate monitoring: These patients require invasive monitoring even for "moderate-risk" procedures
5. Treating systemic hypotension with pure vasodilators: This worsens RV perfusion

Postoperative Management

Continue monitoring for at least 24 hours postoperatively 1 as the highest mortality occurs in this period. If RV failure progresses:

• Optimize diuretics
• Initiate dobutamine 7, 1
• Consider temporary inhaled nitric oxide or IV epoprostenol under PH specialist guidance 7

Special Consideration for Group 3 PH

Unlike Group 1 PAH where aggressive medical therapy is standard, Group 3 PH management focuses primarily on optimizing the underlying lung disease and avoiding PVR-increasing factors 4. The evidence for PAH-targeted therapies in Group 3 is limited, though sildenafil may benefit select COPD-PH patients with severely elevated PVR and preserved FEV₁ 4.